Indonesia's Ministry of Health and Philips to deliver nationwide coverage of advanced image-guided therapy systems in Indonesia, expanding access to cardiac, stroke and cancer care in all 38 provinces
Initiative brings minimally invasive care to millions of cardiac, stroke and cancer patients in Indonesia
Combines cutting-edge treatment technology, services and training to strengthen Indonesia's health infrastructure
Amsterdam, the Netherlands and Jakarta, Indonesia – In a major step toward transforming healthcare delivery, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and the Indonesia's Ministry of Health today announced plans to deploy state-of-the-art image-guided therapy systems nationwide, as part of their signed agreements, under the Strengthening Indonesia's Healthcare Referral Network (SIHREN) project.
The landmark agreements, recently awarded to Philips after an international, competitive bidding process, combine cutting-edge treatment technology, services and training to strengthen Indonesia's health infrastructure. The initiative aims to transform the country's treatment for heart disease, stroke and cancer – Indonesia's leading causes of death – by expanding access to cutting-edge technologies and care in all 38 provinces, from Aceh to Papua. This initiative is set to benefit millions of patients across Indonesia.
The SIHREN project is an ambitious effort jointly funded by the World Bank and other multilateral development banks to support Indonesia's health transformation agenda by significantly improving referral healthcare.
Challenges in ensuring equitable access to healthcare
With a population exceeding 280 million, Indonesia is the world's fourth most populous nation. As a vast archipelago of over 17,000 islands, it faces significant challenges in ensuring equitable access to healthcare. The country is also grappling with a surge in non-communicable diseases (NCDs) such as heart disease, stroke and cancer – conditions projected to impose a staggering economic burden of USD 4.47 trillion [1]. And yet, advanced care for these illnesses remains largely centralized on the densely populated island of Java, leaving much of the country underserved.
The initiative will establish a nationwide network of advanced image-guided therapy rooms, dramatically expanding access to minimally invasive treatments across hundreds of hospitals in all 38 provinces. The Ministry of Health has made a long-term commitment to delivering nationwide coverage of the Azurion platform, aligned to local hospital infrastructure and patient population needs.
A study published in the Journal of Minimally Invasive Surgery [2] found that minimally invasive techniques significantly reduce postoperative pain, recovery time, and hospital stays compared to traditional open surgeries.
'Delivering better care for more people requires strong partnerships and the best innovations,' said Roy Jakobs, CEO of Royal Philips. 'We're honored to be Indonesia's partner of choice to deliver our innovation directly where it's needed most. More patients in Indonesia will now have access to better care.'
'Minimally invasive care is life-changing for patients, unlocking treatment options that were once unimaginable. With small incisions, such targeted treatments can mean shorter hospital stays, fewer complications and quicker recoveries for patients,' said Carla Goulart Peron, Chief Medical Officer at Philips. 'From opening heart-attack-causing blockages, to treating strokes and targeting cancer tumors, image-guided, minimally invasive therapy will be a game-changer for NCD care in Indonesia.'
Philips maintains a strong footprint in Indonesia, employing over 3,900 people across 12 cities and operating a manufacturing facility in Batam for its Personal Health businesses. The Philips Foundation recently launched a major partnership with World Child Cancer to advance early detection of childhood cancers across the country.
'We remain committed to supporting healthcare transformation by delivering innovations that provide better outcome for patient and improve experience for healthcare workers,' said Astri R. Dharmawan, President Director of Philips Indonesia. 'Our combined efforts with the Indonesian government will help close healthcare gaps and bring us closer to a Healthy Indonesia.'
[1] https://www3.weforum.org/docs/WEF_The_Economics_of_non_Disease_Indonesia_2015.pdf
[2] https://pubmed.ncbi.nlm.nih.gov/14746519/
For further information, please contact:
Michael FuchsGlobal External Relations Director, PhilipsTel.: +31 614 869 261
E-mail: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Jim Cramer Discusses the Uncertainty Around UnitedHealth
UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer commented on. When a caller inquired about the company, Cramer said: 'I have long known, this is something I learned probably in my second decade of trading or investing: You do not buy or sell something where you have no idea what is really happening. And at UnitedHealth, there isn't anyone other than the CEO and probably 52,000 lawyers who has any idea what's going on.' Ken Wolter/ UnitedHealth Group Incorporated (NYSE:UNH) provides health benefits, pharmacy care, data analytics, and care delivery services, serving individuals, employers, and public-sector programs. In a July episode, Cramer called the stock 'very, very tricky,' as he remarked: 'UnitedHealth is very, very tricky, and it might be a long-term turn, but I will tell you this, Steve Hemsley is the only person I know who could possibly turn this thing around. Hemsley's back as CEO, he was amazing. I think you have to have fortitude to be in it. I don't like the situation because there's so many winners, as you say, but at least I want people to know that I think Hemsley's is the real deal.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
3 hours ago
- USA Today
UnitedHealth stock is having its worst year since 2008. Can it recover?
The healthcare giant's value has been in free fall this year as bad news continues to pile up. For years UnitedHealth Group (NYSE: UNH) has normally been a reliable dividend stock. But an abysmal start to 2025 has wiped out many of the gains that investors have achieved in recent years, with its five-year return now in negative territory. Year to date, the stock has fallen by nearly 45%, which is by no means normal for the healthcare stock. In fact, this is the worst it has performed since the Great Recession, when it tumbled by more than 54% in 2008. The big questions many investors are likely asking today are: Can it recover? Or is there more of a downfall to come for this once seemingly unstoppable stock? Big declines aren't the norm for UnitedHealth The past few years haven't been all that great for UnitedHealth, but by and large, this has been a fairly strong stock to own. It has typically outperformed the market. And outside of 2024 — when it was down 4% — the last time it finished a year in the red was (as noted) back in 2008, when the U.S. economy was in the midst of the Great Recession and the stock lost more than half of its value. Not only has UnitedHealth normally been a safe stock, it's also been a tremendous growth stock. Consider that if you invested $10,000 into its shares at the end of 2003, then 20 years later your investment would have been worth $181,000. But if you hung on until now, that investment would have fallen to a value of $101,000. While that's still a good return, it spotlights just how significant the decline has been this year, for a stock that's typically known for being a solid long-term investment. Still, the past doesn't predict the future. Why the company might face a tough road ahead The problem with UnitedHealth right now is that it's facing many challenges. Medical costs are up, and there's a lot of uncertainty in healthcare as the federal government looks to cut costs. Meanwhile, the Department of Justice is reportedly looking into UnitedHealth's billing practices. The danger is that the company may face financial repercussions and other headwinds, such as having to change its practices — or at the very least, incurring higher-than-typical costs due to greater utilization rates. The latter, however, may be a shorter-term trend. Either way, this is a business known for consistently growing its operations, and that may not be a sure thing anymore. While UnitedHealth generated a healthy profit of more than $14.4 billion on revenue of $400.3 billion in 2024, investor concerns about long-term growth appear to be weighing on the stock. In May, the company suspended its outlook for the year; it also announced a change in CEO, with Andrew Witty stepping down for personal reasons and former CEO Stephen Hemsley taking over. Should you buy UnitedHealth stock today? While UnitedHealth stock has done well in previous years, that doesn't mean that it's a surefire bet to rebound soon. The good news is that it still has solid fundamentals. Since it's a key health insurer in the U.S., I'd be hesitant to count it out in the long run. There's some near-term risk and even some long-term uncertainty about how all the changes in the healthcare industry might pan out. But the stock is trading at levels it hasn't been at since 2020, and its valuation is just 12 times its trailing earnings. I think that gives it a good enough margin of safety at its current price, and that buying it today might prove to be a solid move. As long as you're willing to be patient, this can be a good stock to buy and hold. David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. The Motley Fool is a USA TODAY content partner offering financial news, analysis and commentary designed to help people take control of their financial lives. Its content is produced independently of USA TODAY. Should you invest $1,000 in UnitedHealth Group right now? Offer from the Motley Fool: Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks »
Business Wire
6 hours ago
- Business Wire
Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Philips, a global leader in health technology, today announced a plan for new investments of more than USD 150 million in U.S. manufacturing and research and development (R&D). As part of today's announcement, Philips unveiled the expansion of its Reedsville, PA, manufacturing facility, which produces AI-enabled ultrasound systems for hospitals across the U.S. These investments come on top of Philips' annual USD 900 million R&D investment in the U.S. as well as investments in nearly 17,000 colleagues across 40 facilities in the United States. Philips has employees in every U.S. state supporting innovations used by clinicians and patients in 90% of hospitals across the country. The investment announced today by Philips includes the expansion of its Reedsville, PA, site and the recently announced expansion of Philips' Image Guided Therapy facility in Plymouth, MN. It also includes additional manufacturing and R&D projects which will come over the next several years to support the company's growth in the U.S. The Reedsville site, which currently manufactures transducers, will also customize the software and configurations of ultrasound systems for specific clinical procedures in cardiovascular, general and maternal care following the expansion. As an example, Philips' industry-leading CV ultrasound platform delivers advanced tools to help doctors diagnose structural heart and coronary artery disease quickly and confidently [1]. 'The proposed planned expansion of our manufacturing facilities is a demonstration of our deep commitment to the U.S. region,' said Jeff DiLullo, Chief Region Leader, Philips North America. 'Each year, Philips spends $900 million in R&D in the U.S. to drive innovation and deliver cutting-edge technology that empowers healthcare professionals to diagnose, treat and monitor patients more effectively. Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.' The expansion of the Reedsville site is expected to add 24,000 square feet of manufacturing space in addition to 40,000 square feet of warehouse space and is expected to create 120 skilled manufacturing jobs. The recently announced expansion of Philips' image-guided therapy facility in Plymouth, MN, which includes the construction of a new medtech training center, is expected to create over 150 new jobs. [1] Philips ultrasound: The next dimension in echocardiography About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at Forward-looking statements and other important information This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
